13F-HR filed by BB BIOTECH AG
BB BIOTECH AG filed this 13F-HR for the quarter ended 2013-06-30, filed 2013-08-14, with 23 holding rows worth $1,388,135,000.
- Accession
- 0000950123-13-006435
- Filer
- CIK 924223
- Filed
- 2013-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2013
A holdings report, 23 entries on the cover page, a total value of $1,388,135,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,388,135,000 with VALUE read as thousands by filing date, 13F file number 028-06964. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerBiotech Focus N.V. 028-11193
- included managerBiotech Invest N.V. 028-11191
- included managerBiotech Target N.V. 028-11189
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CELGENE CORP | 151020104 | COM | 2,150,186 | $251,529,000 | thousands by filing date | |
| ISIS PHARMACEUTICALS INC | 464330109 | COM | 7,769,172 | $208,758,000 | thousands by filing date | |
| Gilead Sciences,Inc. | 375558103 | COM | 3,700,000 | $189,699,000 | thousands by filing date | |
| INCYTE CORP COM | 45337C102 | Stock | 5,357,149 | $117,857,000 | thousands by filing date | |
| Vertex Pharmaceuticals Incorporated | 92532F100 | COM | 1,404,445 | $112,440,000 | thousands by filing date | |
| ALEXION PHARMACEUTICALS INC | 015351109 | COM | 778,126 | $71,774,000 | thousands by filing date | |
| MEDIVATION INC | 58501N101 | COM | 1,449,706 | $71,326,000 | thousands by filing date | |
| ARIAD PHARMACEUTICALS INC | 04033A100 | COM | 3,115,371 | $54,488,000 | thousands by filing date | |
| IMMUNOGEN INC | 45253H101 | COMMON STOCK | 3,262,094 | $54,118,000 | thousands by filing date | |
| ONYX PHARMACEUTICALS INC | 683399109 | COM | 546,500 | $47,447,000 | thousands by filing date | |
| HALOZYME THERAPEUTICS INC COM | 40637H109 | Stock | 5,646,519 | $44,890,000 | thousands by filing date | |
| THERAVANCE INC | 88338T104 | COMMON STOCK | 888,244 | $34,224,000 | thousands by filing date | |
| ENDOCYTE INC | 29269A102 | COM | 2,339,345 | $30,716,000 | thousands by filing date | |
| OPTIMER PHARMACEUTICALS INC | 68401H104 | COM | 1,446,700 | $20,934,000 | thousands by filing date | |
| INFINITY PHARMACEUTICALS INC | 45665G303 | COM | 1,089,828 | $17,646,000 | thousands by filing date | |
| ALNYLAM PHARMACEUTICALS INC COM | 02043Q107 | Stock | 454,800 | $14,099,000 | thousands by filing date | |
| ACHILLION PHARMACEUTICALS IN | 00448Q201 | COM | 1,679,340 | $13,737,000 | thousands by filing date | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 178,028 | $9,923,000 | thousands by filing date | |
| MEDICINES CO | 584688105 | COM | 302,993 | $9,320,000 | thousands by filing date | |
| IDENIX PHARMACEUTICALS INC | 45166R204 | COM | 1,250,000 | $4,513,000 | thousands by filing date | |
| DENDREON CORP | 24823Q107 | COM | 1,014,800 | $4,181,000 | thousands by filing date | |
| TRIUS THERAPEUTICS INC | 89685K100 | COM | 280,000 | $2,268,000 | thousands by filing date | |
| SYNAGEVA BIOPHARMA CORP | 87159A103 | COM | 53,549 | $2,248,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-13-006435 | this filing | 2013-08-14 | acceptance time not in the bulk data set |